摘要
目的总结治疗伏格特-小柳-原田综合征（VKH）继发视网膜新生血管的有效方法。方法回顾分析我院16例（20只眼）经玻璃体腔注射贝伐单抗联合中药治疗的VKH综合征继发视网膜下新生血管患者的临床资料,评价其疗效和安全性。结果治疗后视力小于0.1由3例减少到1例,视力0.1~0.5的由12例减少到4例,视力达到0.6~0.9的由4例增加到11例,另有4例视力提高到1.0。所有因新生血管引发的视网膜或玻璃体（少量）出血均大部分吸收;OCT提示20只眼黄斑及视盘的水肿均有不同程度减轻;FFA显示有10只眼继发的视网膜下新生血管已见萎缩和退化;9只眼荧光渗漏明显减弱;有1只眼治疗后第2天眼压升高,局部点用降眼压药可控制,考虑玻璃体注药后一过性高眼压,余未见明显并发症。治疗总有效率95%。结论单次玻璃体腔注射贝伐单抗联合中药治疗VKH综合征继发视网膜下新生血管有较好的疗效。
OBJECTIVE To explore an effective treatment for retinal neovascularization secondary to Vogt-Koyanagi-Harada syndrome（VKH）. METHODS Sixteen patients（20 eyes） of VKH syndrome with secondary retinal neovascularization were treated by intravitreal injection bevacizumab in combination with herbs from 2011 to 2014. Then recorded the clinical data to evaluate the effect and security of this therapeutic plan. RESULTS After treatment, cases with vision less than 0.1 decreased from 3 to 1, 12 participants with vision between 0.1 to 0.5 reduced to 4; cases with vision between 0.6-0.9 patients increased from 2 to 11, and 4 cases were improved to 1.0; All retina or vitreous hemorrhage（small amount） due to angiogenesis were most absorption; optical coherence tomograghy（OCT） indicated that 20 eyes of macular or optic disc edema alleviated to some extent; fundus fluorescence angiography（FFA） showed secondary subretinal neovascularization of 10 eyes manifested with signs of atrophy and degeneration; nine cases of fluorescent leakage decreased significantly; One eye suffered intraocular pressure elevation 2 days after treatment, and was controlled by anti-ocular pressure agents. It was considered as transient glucocorticoid-induced glaucoma. Other complications were not observed in this study. The total effective rate was 95%.CONCLUSIONS Bevacizumab intravitreal injection combined with herbs for the treatment of retinal neovascularization secondary to VKH yielded favorable curative effect.
出处
《中国中医眼科杂志》
2016年第2期89-92,共4页
China Journal of Chinese Ophthalmology
